Amgen Inc. (NASDAQ: AMGN) is a company recently discussed by Jim Cramer for the need to expand its portfolio of medicines. The company manufactures human therapeutics for cancer, cardiovascular, inflammatory, and bone disorders. Cramer highlighted the benefits of Amgen’s MariTide, which only requires a monthly injection compared to weekly ones like other treatments. The market’s response to recent company news was negative, causing a stock sell-off. The Phase 1 trial data showed promising results with lower starting doses of MariTide resulting in fewer side effects.

Read more at Yahoo Finance: “They Have A Lot of Good Medicines”